Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism Export

@article{citeulike:4681341, abstract = {Context: Patients with persistent primary hyperparathyroidism (PHPT) after parathyroidectomy or with contraindications to parathyroidectomy often require chronic treatment for hypercalcemia.Objective: To assess the ability of the calcimimetic, cinacalcet, to reduce serum calcium in patients with intractable PHPT.Design: Open-label, single-arm study comprising a titration phase of variable duration (2-16 wk) and a maintenance phase of up to 136 wk.Setting: Twenty-three centers in Europe, the United States, and Canada.Patients: Seventeen patients with intractable PHPT and serum calcium > 12.5 mg/dl (3.1 mmol/liter).Intervention: During the titration phase cinacalcet dosages were titrated every 2 wk (30 mg twice daily to 90 mg four times daily) for 16 wk until serum calcium was [\≤] 10 mg/dl (2.5 mmol/liter). If serum calcium increased during the maintenance phase, additional increases in the cinacalcet dose were permitted.Main Outcome Measure: The primary endpoint was the proportion of patients experiencing a reduction in serum calcium of [\≥] 1 mg/dl (0.25 mmol/liter) at the end of the titration phase.Results: Mean {+/-} SD baseline serum calcium was 12.7 {+/-} 0.8 mg/dl (3.2 {+/-} 0.2 mmol/liter). At the end of titration, a [\≥] 1 mg/dl reduction in serum calcium was achieved in 15 patients (88\%). Fifteen patients (88\%) experienced treatment-related adverse events, none of which were serious. The most common adverse events were nausea, vomiting, and paresthesias.Conclusions: In patients with intractable PHPT, cinacalcet reduces serum calcium, is generally well tolerated, and has the potential to fulfill an unmet medical need. 10.1210/jc.2008-2640}, author = {Marcocci, Claudio and Chanson, Philippe and Shoback, Dolores and Bilezikian, John and Fernandez-Cruz, Laureano and Orgiazzi, Jacques and Henzen, Christoph and Cheng, Sunfa and Ren and Lu, John and Peacock, Munro}, citeulike-article-id = {4681341}, citeulike-linkout-0 = {http://dx.doi.org/10.1210/jc.2008-2640}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19470620}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19470620}, day = {26}, doi = {10.1210/jc.2008-2640}, journal = {J Clin Endocrinol Metab}, keywords = {calcium, hyperparathyroidism, therapy}, month = {May}, pages = {jc.2008-2640+}, posted-at = {2009-05-30 16:15:24}, priority = {2}, title = {Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism}, url = {http://dx.doi.org/10.1210/jc.2008-2640}, year = {2009} }

TY - JOUR ID - citeulike:4681341 L3 - citeulike-article-id:4681341 N2 - Context: Patients with persistent primary hyperparathyroidism (PHPT) after parathyroidectomy or with contraindications to parathyroidectomy often require chronic treatment for hypercalcemia.Objective: To assess the ability of the calcimimetic, cinacalcet, to reduce serum calcium in patients with intractable PHPT.Design: Open-label, single-arm study comprising a titration phase of variable duration (2-16 wk) and a maintenance phase of up to 136 wk.Setting: Twenty-three centers in Europe, the United States, and Canada.Patients: Seventeen patients with intractable PHPT and serum calcium > 12.5 mg/dl (3.1 mmol/liter).Intervention: During the titration phase cinacalcet dosages were titrated every 2 wk (30 mg twice daily to 90 mg four times daily) for 16 wk until serum calcium was [≤] 10 mg/dl (2.5 mmol/liter). If serum calcium increased during the maintenance phase, additional increases in the cinacalcet dose were permitted.Main Outcome Measure: The primary endpoint was the proportion of patients experiencing a reduction in serum calcium of [≥] 1 mg/dl (0.25 mmol/liter) at the end of the titration phase.Results: Mean {+/-} SD baseline serum calcium was 12.7 {+/-} 0.8 mg/dl (3.2 {+/-} 0.2 mmol/liter). At the end of titration, a [≥] 1 mg/dl reduction in serum calcium was achieved in 15 patients (88%). Fifteen patients (88%) experienced treatment-related adverse events, none of which were serious. The most common adverse events were nausea, vomiting, and paresthesias.Conclusions: In patients with intractable PHPT, cinacalcet reduces serum calcium, is generally well tolerated, and has the potential to fulfill an unmet medical need. 10.1210/jc.2008-2640 JF - J Clin Endocrinol Metab TI - Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism SP - jc.2008-2640 KW - calcium KW - hyperparathyroidism KW - therapy AU - Marcocci, Claudio AU - Chanson, Philippe AU - Shoback, Dolores AU - Bilezikian, John AU - Fernandez-Cruz, Laureano AU - Orgiazzi, Jacques AU - Henzen, Christoph AU - Cheng, Sunfa AU - Ren AU - Lu, John AU - Peacock, Munro PY - 2009/05/26/ UR - http://dx.doi.org/10.1210/jc.2008-2640 ER -